Arenaviruses and hantaviruses: From epidemiology and genomics to antivirals

Antiviral Research

Volumn 90, Issue 2, 2011, Pages 102-114

  Charrel, R N ^a   Coutard, B ^b   Baronti, C ^a   Canard, B ^b   Nougairede, A ^a   Frangeul, A ^b   Morin, B ^b   Jamal, S ^b   Schmidt, C L ^e   Hilgenfeld, R ^e   Klempa, B ^c,d   de Lamballerie, X ^a  

^a Aix Marseille University IRD 190 Inserm 1207   (France)

^b Centre National de la Recherche Scientifique   (France)

^c INSTITUTE OF VIROLOGY   (Slovakia)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Antiviral therapy; Arenavirus; Hantavirus; Zoonosis

Indexed keywords

DIHYDROLIPOAMIDE DEHYDROGENASE; FATTY ACID BINDING PROTEIN; FAVIPIRAVIR; GENOMIC DNA; HANTAVAX; NUCLEOCAPSID PROTEIN; RIBAVIRIN; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ARENAVIRUS; DISEASE CONTROL; FOOT AND MOUTH DISEASE; GENOME ANALYSIS; HANTAVIRUS; HEMORRHAGIC FEVER; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; ARENAVIRUS; DRUG DISCOVERY; GENOMICS; HANTAVIRUS; HANTAVIRUS INFECTIONS; HUMANS; VIRAL PROTEINS; VIRUS REPLICATION;

ARENAVIRUS; HANTAVIRUS; LASSA VIRUS; ORTHOBUNYAVIRUS; RNA VIRUSES; RODENTIA;

EID: 79955646928     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.02.009     Document Type: Review

References (142)

1. Albiol Matanic V.C., Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int. J. Antimicrob. Agents 2004, 23:382-389.
2. Amman B.R., Pavlin B.I., Albariño C.G., Comer J.A., Erickson B.R., Oliver J.B., Sealy T.K., Vincent M.J., Nichol S.T., Paddock C.D., Tumpey A.J., Wagoner K.D., Glauer R.D., Smith K.A., Winpisinger K.A., Parsely M.S., Wyrick P., Hannafin C.H., Bandy U., Zaki S., Rollin P.E., Ksiazek T.G. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. Emerg. Infect. Dis. 2007, 13:719-725.
3. Arai S., Song J.W., Sumibcay L., Bennett S.N., Nerurkar V.R., Parmenter C., Cook J.A., Yates T.L., Yanagihara R. Hantavirus in northern short-tailed shrew, United States. Emerg. Infect. Dis. 2007, 13:1420-1423.
4. Arai S., Bennett S.N., Sumibcay L., Cook J.A., Song J.W., Hope A., Parmenter C., Nerurkar V.R., Yates T.L., Yanagihara R. Phylogenetically distinct hantaviruses in the masked shrew (textitSorex cinereus) and dusky shrew (Sorex monticolus) in the United States. Am. J. Trop. Med. Hyg. 2008, 78:348-351.
5. Arai S., Ohdachi S.D., Asakawa M., Kang H.J., Mocz G., Arikawa J., Okabe N., Yanagihara R. Molecular phylogeny of a newfound hantavirus in the Japanese shrew mole (Urotrichus talpoides). Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16296-16301.
6. Archer A.M., Rico-Hesse R. High genetic divergence and recombination in Arenaviruses from the Americas. Virology 2002, 304:274-281.
7. Armstrong C., Lillie R.D. Experimental lymphocytic choriomeningitis of monkeys and mice produced by a virus encountered in studies of the 1933 St Louis encephalitis epidemic. Public Health Rep. 1934, 49:1019-1027.
8. Asnis D.S., Muana O., Kim do G., Garcia M., Rollin P.E., Slavinski S. Lymphocytic choriomeningitis virus meningitis, New York, NY, USA, 2009. Emerg. Infect. Dis. 2010, 16:328-330.
9. Asper M., Sternsdorf T., Hass M., Drosten C., Rhode A., Schmitz H., Gunther S. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J. Virol. 2004, 78:3162-3169.
10. Barton L.L. Human infection with lymphocytic choriomeningitis virus. Emerg. Infect. Dis. 2010, 16:1046-1047.
11. Barton L.L., Budd S.C., Morfitt W.S., Peters C.J., Ksiazek T.G., Schindler R.F., Yoshino M.T. Congenital lymphocytic choriomeningitis virus infection in twins. Pediatr. Infect. Dis. J. 1993, 12:942-946.
12. Barton L.L., Hyndman N.J. Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. Pediatrics 2000, 105:E35.
13. Bergthaler A., Gerber N.U., Merkler D., Horvath E., de la Torre J.C., Pinschewer D.D. Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog. 2006, 2:e51.
14. Berrow N.S., Büssow K., Coutard B., Diprose J., Ekberg M., Folkers G.E., Levy N., Lieu V., Owens R.J., Peleg Y., Pinaglia C., Quevillon-Cheruel S., Salim L., Scheich C., Vincentelli R., Busso D. Recombinant protein expression and solubility screening in Escherichia coli: a comparative study. Acta Crystallogr. D: Biol. Crystallogr. 2006, 62:1218-1226.
15. Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Lund S., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., Hruby D.E. Identification and characterization of potent small molecule inhibitor of haemorrhagic fever New World arenaviruses. Antiviral Res. 2006, 69:86-97.
16. Borden K.L.B., Campbell Dwyer E.J., Salvato M.S. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J. Virol. 1998, 72:758-766.
17. Borden K.L.B., Campbell Dwyer E.J., Carlile G.W., Djavani M., Salvato M.S. Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P protein. J. Virol. 1998, 72:3819-3826.
18. Bouloy M., Pardigon N., Vialat P., Gerbaud S., Girard M. Characterization of the 5' and 3' ends of viral messenger RNAs isolated from BHK21 cells infected with Germiston virus (Bunyavirus). Virology 1990, 175:50-58.
19. Bowen M.D., Peters C.J., Nichol S.T. The phylogeny of New World (Tacaribe complex) arenaviruses. Virology 1996, 219:285-290.
20. Bowen M.D., Peters C.J., Nichol S.T. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol. Phylogenet. Evol. 1997, 8:301-316.
21. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S., Moshkoff D., Zapata J., Tikhonov I., Patterson J., Carrion R., Ticer A., Brasky K., Lukashevich I.S. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345:299-304.
22. Briese T., Paweska J.T., McMullan L.K., Hutchison S.K., Street C., Palacios G., Khristova M.L., Weyer J., Swanepoel R., Egholm M., Nichol S.T., Lipkin W.I. Genetic detection and characterization of Lujo virus, a new haemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 2009, 5:e1000455.
23. Cajimat M.N., Milazzo M.L., Borchert J.N., Abbott K.D., Bradley R.D., Fulhorst C.F. Diversity among Tacaribe serocomplex viruses (family Arenaviridae) naturally associated with the Mexican woodrat (Neotoma mexicana). Virus Res. 2008, 133:211-217.
24. Cajimat M.N., Milazzo M.L., Bradley R.D., Fulhorst C.F. Catarina virus, an arenaviral species principally associated with Neotoma micropus (southern plains woodrat) in Texas. Am. J. Trop. Med. Hyg. 2007, 77:732-736.
25. Campbell Dwyer E.J., Lai H., MacDonald R.C., Salvato M.S., Borden K.L.B. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner. J. Virol. 2000, 74:3293-3300.
26. Castilla V., Larzabal M., Sgalippa N.A., Wachsman M.B., Coto C.E. Antiviral mode of action of a synthetic brassinosteroid against Junin virus replication. Antiviral Res. 2005, 68:88-95.
27. Centers for Disease Control and Prevention Fatal illnesses associated with a New World arenavirus - California, 1999-2000. MMWR Morb. Mortal. Wkly. Rep. 2000, 49:709-711.
28. Centers for Disease Control and Prevention Lymphocytic choriomeningitis virus infection in organ transplant recipients - Massachusetts, Rhode Island, 2005. MMWR Morb. Mortal. Wkly. Rep. 2005, 54:537-539.
29. Centers for Disease Control and Prevention Survey of lymphocytic choriomeningitis virus diagnosis and testing - Connecticut, 2005. MMWR Morb. Mortal. Wkly. Rep. 2006, 55:398-399.
30. Centers for Disease Control and Prevention Brief report: lymphocytic choriomeningitis virus transmitted through solid organ transplantation - Massachusetts, 2008. MMWR Morb. Mortal. Wkly. Rep. 2008, 57:799-801.
31. Chapman L.E., Mertz G.J., Peters C.J., Jolson H.M., Khan A.S., Ksiazek T.G., Koster F.T., Baum K.F., Rollin P.E., Pavia A.T., Holman R.C., Chris-tenson J.C., Rubin P.J., Behrman R.E., Bell L.J., Simpson G.L., Sadek R.F. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir. Ther. 1999, 4:211-219.
32. Charrel R.N., de Lamballerie X., Fulhorst C.F. The Whitewater Arroyo virus: natural evidence for genetic recombination among Tacaribe serocomplex viruses (family Arenaviridae). Virology 2001, 283:161-166.
33. Charrel R.N., Feldmann H., Fulhorst C.F., Khelifa R., de Chesse R., de Lamballerie X. Phylogeny of New World arenaviruses based on the complete coding sequences of the small genomic segment identified an evolutionary lineage produced by intrasegmental recombination. Biochem. Biophys. Res. Commun. 2002, 296:1118-1124.
34. Charrel R.N., Lemasson J.J., Garbutt M., Khelifa R., De Micco P., Feldmann H., de Lamballerie X. New insights into the evolutionary relationships between arenaviruses provided by comparative analysis of small and large segment sequences. Virology 2003, 317:191-196.
35. Charrel R.N., Retornaz K., Emonet S., Noel G., Chaumoitre K., Minodier P., Girard N., Garnier J.M., de Lamballerie X. Acquired hydrocephalus caused by a variant lymphocytic choriomeningitis virus. Arch. Intern. Med. 2006, 166:2044-2046.
36. Charrel R.N., de Lamballerie X., Emonet S. Phylogeny of the genus Arenavirus. Curr. Opin. Microbiol. 2008, 11:362-368.
37. Cho H.W., Howard C.R., Lee H.W. Review of an inactivated vaccine against hantaviruses. Intervirology 2002, 45(4-6):328-333.
38. Choi K.H., Groarke J.M., Young D.C., Kuhn R.J., Smith J.L., Pevear D.C., Rossmann M.G. The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4425-4430.
39. Chung D.H., Kumarapperuma S.C., Sun Y., Li Q., Chu Y.K., Arterburn J.B., Parker W.B., Smith J., Spik K., Ramanathan H.N., Schmaljohn C.S., Jonsson C.B. Synthesis of 1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Res. 2008, 79:19-27.
40. Coutard B., Canard B. The VIZIER project: overview; expectations; and achievements. Antiviral Res. 2010, 87(2):85-94.
41. Coutard B., Gorbalenya A.E., Snijder E.J., Leontovich A.M., Poupon A., De Lamballerie X., Charrel R., Gould E.A., Gunther S., Norder H., Klempa B., Bourhy H., Rohayem J., L'hermite E., Nordlund P., Stuart D.I., Owens R.J., Grimes J.M., Tucker P.A., Bolognesi M., Mattevi A., Coll M., Jones T.A., Aqvist J., Unge T., Hilgenfeld R., Bricogne G., Neyts J., La Colla P., Puerstinger G., Gonzalez J.P., Leroy E., Cambillau C., Romette J.L., Canard B. The VIZIER project: preparedness against pathogenic RNA viruses. Antiviral Res. 2008, 78:37-46.
42. De Ory F., Gegúndez M.I., Fedele C.G., Sánchez-Seco M.P. Toscana virus, West Nile virus and lymphochoriomeningitis virus as causing agents of aseptic meningitis in Spain. Med. Clin. (Barc). 2009, 132:587-590.
43. Delgado S., Erickson B.R., Agudo R., Blair P.J., Vallejo E., Albariño C.G., Vargas J., Comer J.A., Rollin P.E., Ksiazek T.G., Olson J.G., Nichol S.T. Chapare virus, a newly discovered arenavirus isolated from a fatal haemorrhagic fever case in Bolivia. PLoS Pathog. 2008, 4:e1000047.
44. Dias A., Bouvier D., Crépin T., McCarthy A.A., Hart D.J., Baudin F., Cusack S., Ruigrok R.W. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009, 458:914-918.
45. Dong G.M., Han L., An Q., Liu W.X., Kong Y., Yang L.H. Immunization effect of purified bivalent vaccine to haemorrhagic fever with renal syndrome manufactured from primary cultured hamster kidney cells. Chin. Med. J. (Engl.) 2005, 118(9):766-768.
46. Egloff M.P., Benarroch D., Selisko B., Romette J.L., Canard B. An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 2002, 21(11):2757-2768.
47. Emonet S., Retornaz K., Gonzalez J.P., de Lamballerie X., Charrel R.N. Mouse-to-human transmission of variant lymphocytic choriomeningitis virus. Emerg. Infect. Dis. 2007, 13:472-475.
48. Emonet S.F., Seregin A.V., Yun N.E., Poussard A.L., Walker A.G., de la Torre J.C., Paessler S. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J. Virol. 2011, 85(4):1473-1483.
49. Enria D.A., de Damilano A.J., Briggiler A.M., Ambrosio A.M., Fernández N.J., Feuillade M.R., Maiztegui J.I. Late neurologic syndrome in patients with Argentinian hemorrhagic fever treated with immune plasma. Medicina (B Aires) 1985, 45:615-620.
50. Enria D.A., Briggiler A.M., Fernandez N.J., et al. Dose of neutralising antibodies for Argentine haemorrhagic fever. Lancet 1984, 2:255-256.
51. Enria D.A., Maiztegui J.I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 1994, 23(1):23-31.
52. Ferres M., Vial P., Marco C., Yanez L., Godoy P., Castillo C., Hjelle B., Delgado I., Lee S.J., Mertz G.J. Andes Virus Household Contacts Study Group. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in Chile. J. Infect. Dis. 2007, 195:1563-1571.
53. Fischer S.A., Graham M.B., Kuehnert M.J., Kotton C.N., Srinivasan A., Marty F.M., Comer J.A., Guarner J., Paddock C.D., DeMeo D.L., Shieh W.J., Erickson B.R., Bandy U., DeMaria A., Davis J.P., Delmonico F.L., Pavlin B., Likos A., Vincent M.J., Sealy T.K., Goldsmith C.S., Jernigan D.B., Rollin P.E., Packard M.M., Patel M., Rowland C., Helfand R.F., Nichol S.T., Fishman J.A., Ksiazek T., Zaki S.R. LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 2006, 354:2235-2249.
54. Flatz L., Rieger T., Merkler D., Bergthaler A., Regen T., Schedensack M., Bestmann L., Verschoor A., Kreutzfeldt M., Brück W., Hanisch U.K., Günther S., Pinschewer D.D. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 2010, 6(3):e1000836.
55. Franze-Fernández M.T., Zetina C., Iapalucci S., Lucero M.A., Bouissou C., López R., Rey O., Daheli M., Cohen G.N., Zakin M.M. Molecular structure and early events in the replication of Tacaribe arenavirus S RNA. Virus Res. 1987, 7:309-324.
56. Garci{dotless}á C.C., Djavani M., Topisirovic I., Borden K.L.B., Salvato M.S., Damonte E.B. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J. Gen. Virol. 2006, 87:1217-1228.
57. Garcin D., Kolakofsky D. A novel mechanism for the initiation of Tacaribe arenavirus genome replication. J. Virol. 1990, 64:6196-6203.
58. Gavrilovskaya I.N., Gorbunova E.E., Mackow N.A., Mackow E.R. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. J. Virol. 2008, 82:5797-5806.
59. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Ströher U., Fernando L., Daddario K.M., Guttieri M.C., Mothé B.R., Larsen T., Hensley L.E., Jahrling P.B., Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005, 2:183.
60. Gorbalenya A.E., Lieutaud P., Harris M.R., Coutard B., Canard B., Kleywegt G.J., Kravchenko A.A., Samborskiy D.V., Sidorov I.A., Leontovich A.M., Jones T.A. Practical application of bioinformatics by the multidisciplinary VIZIER consortium. Antiviral Res. 2010, 87(2):95-110.
61. Gowen B.B., Wong M.H., Larson D., Ye W., Jung K.H., Sefing E.J., Skirpstunas R., Smee D.F., Morrey J.D., Schneller S.W. Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS One 2010, 5(9). pii: e12760.
62. Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008, 3:e3725.
63. Gowen B.B., Holbrook M.R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 2008, 78:79-90.
64. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., Sidwell R.W. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 2007, 51:3168-3176.
65. Guilligay D., Tarendeau F., Resa-Infante P., Coloma R., Crepin T., Sehr P., Lewis J., Ruigrok R.W., Ortin J., Hart D.J., Cusack S. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat. Struct. Mol. Biol. 2008, 15:500-506.
66. Gunther S., Asper M., Roser C., Luna L.K., Drosten C., Becker-Ziaja B., Borowski P., Chen H.M., Hosmane R.S. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res. 2004, 63:209-215.
67. Hall P.R., Hjelle B., Brown D.C., Ye C., Bondu-Hawkins V., Kilpatrick K.A., Larson R.S. Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade. Antimicrob. Agents Chemother. 2008, 52:2079-2088.
68. Hall P.R., Malone L., Sillerud L.O., Ye C., Hjelle B.L., Larson R.S. Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem. Biol. Drug Des. 2007, 69:180-190.
69. Hass M., Lelke M., Busch C., Becker-Ziaja B., Günther S. Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. J. Virol. 2008, 82:10207-10217.
70. Henttonen H., Buchy P., Suputtamongkol Y., Jittapalapong S., Herbreteau V., Laakkonen J., Chaval Y., Galan M., Dobigny G., Charbonnel N., Michaux J., Cosson J.F., Morand S., Hugot J.P. Recent discoveries of new hantaviruses widen their range and question their origins. Ann. N. Y. Acad. Sci. 2008, 1149:84-89.
71. Hooper J.W., Kamrud K.I., Elgh F., Custer D., Schmaljohn C.S. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 1999, 255(2):269-278.
72. Huggins J.W., Hsiang C.M., Cosgriff T.M., Guang M.Y., Smith J.I., Wu Z.O., LeDuc J.W., Zheng Z.M., Meegan J.M., Wang Q.N., et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of haemorrhagic fever with renal syndrome. J. Infect. Dis. 1991, 164:1119-1127.
73. Huggins J.W., Kim G.R., Brand O.M., McKee K.T. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 1986, 153:489-497.
74. Jabafi I., Selisko B., Coutard B., De Palma A.M., Neyts J., Egloff M.P., Grisel S., Dalle K., Campanacci V., Spinelli S., Cambillau C., Canard B., Gruez A. Improved crystallization of the coxsackievirus B3 RNA-dependent RNA polymerase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2007, 63(Pt 6):495-498.
75. Jin H., Elliott R.M. Characterization of Bunyamwera virus S RNA that is transcribed and replicated by the L protein expressed from recombinant vaccinia virus. J. Virol. 1993, 67:1396-1404.
76. Jonsson C.B., Hooper J., Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008, 78:162-169.
77. Kang H.J., Bennett S.N., Dizney L., Sumibcay L., Arai S., Ruedas L.A., Song J.W., Yanagihara R. Host switch during evolution of a genetically distinct hantavirus in the American shrew mole (Neurotrichus gibbsii). Virology 2009, 388:8-14.
78. Kariwa H., Yoshimatsu K., Arikawa J. Hantavirus infection in East Asia. Comp. Immunol. Microbiol. Infect. Dis. 2007, 30:341-356.
79. Kelley L.A., Sternberg M.J. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 2009, 4:363-371.
80. Khaiboullina S.F., Morzunov S.P., St Jeor S.C. Hantaviruses: molecular biology, evolution and pathogenesis. Curr. Mol. Med. 2005, 5:773-790.
81. Klempa B., Fichet-Calvet E., Lecompte E., Auste B., Aniskin V., Meisel H., Denys C., Koivogui L., ter Meulen J., Krüger D.H. Hantavirus in African wood mouse, Guinea. Emerg. Infect. Dis. 2006, 12:838-840.
82. Klempa B., Fichet-Calvet E., Lecompte E., Auste B., Aniskin V., Meisel H., Barrière P., Koivogui L., ter Meulen J., Krüger D.H. Novel hantavirus sequences in Shrew, Guinea. Emerg. Infect. Dis. 2007, 13:520-522.
83. Klempa B., Tkachenko E.A., Dzagurova T.K., Yunicheva Y.V., Morozov V.G., Okulova N.M., Slyusareva G.P., Smirnov A., Kruger D.H. Haemorrhagic fever with renal syndrome caused by 2 lineages of Dobrava hantavirus, Russia. Emerg. Infect. Dis. 2008, 14:617-625.
84. Klempa B. Hantaviruses and climate change. Clin. Microbiol. 2009, 15:518-523.
85. Krüger D.H., Ulrich R., Lundkvist A. Hantavirus infections and their prevention. Microbes Infect. 2001, 3:1129-1144.
86. Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 2008, 82:10768-10775.
87. Larson R.S., Brown D.C., Ye C., Hjelle B. Peptide antagonists that inhibit Sin Nombre virus and Hantaan virus entry through the β3-integrin receptor. J. Virol. 2005, 79:7319-7326.
88. Lecompte E., ter Meulen J., Emonet S., Daffis S., Charrel R.N. Genetic identification of Kodoko virus, a novel arenavirus of the African pigmy mouse (Mus Nannomys minutoides) in West Africa. Virology 2007, 364:178-183.
89. Lee K.J., Novella I.S., Teng M.N., Oldstone M.B., de La Torre J.C. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 2000, 74:3470-3477.
90. Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 2008, 283:18734-18742.
91. Lopez N., Jácamo R., Franze-Fernández M.T. Transcription and RNA replication of tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J. Virol. 2001, 75:12241-12251.
92. Lukashevich I.S. Generation of reassortants between African arenaviruses. Virology 1992, 188:600-605.
93. Lukashevich I.S., Carrion R., Salvato M.S., Mansfield K., Brasky K., Zapata J., Cairo C., Goicochea M., Hoosien G.E., Ticer A., Bryant J., Davis H., Hammamieh R., Mayda M., Jett M., Patterson J. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008, 26:5246-5254.
94. Maes P., Clement J., Gavrilovskaya I., Van Ranst M. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 2004, 17:481-497.
95. Maes P., Clement J., Van Ranst M. Recent approaches in hantavirus vaccine development. Expert Rev. Vaccines 2009, 8:67-76.
96. Maes P., Klempa B., Clement J., Matthijnssens J., Gajdusek D.C., Krüger D.H., Van Ranst M. A proposal for new criteria for the classification of hantaviruses, based on S and M segment protein sequences. Infect. Genet. Evol. 2009, [Epub ahead of print].
97. Maiztegui J.I., Fernandez N.J., de Damilano A.J. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979, 2:1216-1217.
98. Maiztegui J.I., McKee K.T., Barrera Oro J.G., Harrison L.H., Gibbs P.H., Feuillade M.R., Enria D.A., Briggiler A.M., Levis S.C., Ambrosio A.M., Halsey N.A., Peters C.J. Protective efficacy of a live attenuated vaccine against Argentine haemorrhagic fever. AHF Study Group. J. Infect. Dis. 1998, 177:277-283.
99. Manolaridis I., Wojdyla J.A., Panjikar S., Snijder E.J., Gorbalenya A.E., Berglind H., Nordlund P., Coutard B., Tucker P.A. Structure of the C-terminal domain of nsp4 from feline coronavirus. Acta Crystallogr. D: Biol. Crystallogr. 2009, 65(Pt 8):839-846.
100. Martinez V.P., Bellomo C., San Juan J., Pinna D., Forlenza R., Elder M., Padula P.J. Person-to-person transmission of Andes virus. Emerg. Infect. Dis. 2005, 11:1848-1853.
101. McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr. Top. Med. Microbiol. Immunol. 2002, 262:75-109.
102. McCormick J.B., Webb P.A., Krebs J.W., Johnson K.M., Smith E.S. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 1987, 155:437-442.
103. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314:20-26.
104. Mertz G.J., Miedzinski L., Goade D., Pavia A.T., Hjelle B., Hansbarger C.O., Levy H., Koster F.T., Baum K., Lindemulder A., Wang W., Riser L., Fernandez H., Whitley R.J. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 2004, 39(9):1307-1313. Collaborative Antiviral Study Group.
105. Meyer B.J., Southern P.J. Concurrent sequence analysis of 5' and 3' RNA termini by intramolecular circularization reveals 5' nontemplated bases and 3' terminal heterogeneity for lymphocytic choriomeningitis virus mRNAs. J. Virol. 1993, 67:2621-2627.
106. Milazzo M.L., Cajimat M.N., Haynie M.L., Abbott K.D., Bradley R.D., Fulhorst C.F. Diversity among tacaribe serocomplex viruses (family Arenaviridae) naturally associated with the white-throated woodrat (Neotoma albigula) in the southwestern United States. Vector Borne Zoonotic Dis. 2008, 8:523-540.
107. Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R., de Lamballerie X., Vonrhein C., Lescar J., Bricogne G., Günther S., Canard B. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog. 2010, 6(9). pii: e1001038.
108. Padula P.J., Edelstein A., Miguel S.D., López N.M., Rossi C.M., Rabinovich R.D. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 1998, 241:323-330.
109. Palacios G., Druce J., Du L., Tran T., Birch C., Briese T., Conlan S., Quan P.L., Hui J., Marshall J., Simons J.F., Egholm M., Paddock C.D., Shieh W.J., Goldsmith C.S., Zaki S.R., Catton M., Lipkin W.I. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 2008, 358:991-998.
110. Palacios G., Savji N., Hui J., Travassos da Rosa A., Popov V., Briese T., Tesh R., Lipkin W.I. Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J. Gen. Virol. 2010, 91:1315-1324.
111. Park K., Kim C.S., Moon K.T. Protective effectiveness of hantavirus vaccine. Emerg. Infect. Dis. 2004, 10(12):2218-2220.
112. Peters C.J., Buchmeier M., Rollin P.E., Ksiazek T.G. Arenaviruses. Fields Virology 1996, Lippincott-Raven Publishers. B.N. Fields, D.M. Knipe, P.M. Howley, R.M. Chanock, J.L. Melnick, T.P. Monath, R. Roizman, S.E. Straus (Eds.).
113. Piyasirisilp S., Schmeckpeper B.J., Chandanayingyong D., Hemachudha T., Griffin D.E. Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis. Ann. Neurol. 1999, 45(5):595-600.
114. Plyusnin A., Vapalahti O., Vaheri A. Hantaviruses: genome structure, expression and evolution. J. Gen. Virol. 1996, 77(Pt 11):2677-2687.
115. Raju R., Raju L., Hacker D., Garcin D., Compans R., Kolakofsky D. Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. Virology 1990, 174:53-59.
116. Ramsden C., Holmes E.C., Charleston M.A. Hantavirus evolution in relation to its rodent and insectivore hosts: no evidence for co-divergence. Mol. Biol. Evol. 2009, 26:143-153.
117. Ramsden C., Melo F.L., Figueiredo L.M., Holmes E.C., Zanotto P.M. VGDN Consortium. High rates of molecular evolution in hantaviruses. Mol. Biol. Evol. 2008, 25:1488-1492.
118. Reguera J., Weber F., Cusack S. Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription. PLoS Pathog. 2010, 6(9). pii: e1001101.
119. Rusnak J.M., Byrne W.R., Chung K.N., Gibbs P.H., Kim T.T., Boudreau E.F., Cosgriff T., Pittman P., Kim K.Y., Erlichman M.S., Rezvani D.F., Huggins J.W. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. 2009, 81:68-76.
120. Safronetz D., Hegde N., Ebihara H., Denton M., Kobinger G.P., St Jeor S., Feldmann H., Johnson D.C. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J. Virol. 2009, [Epub ahead of print].
121. Salvato M.S., Clegg J.C.S., Buchmeier M.J., Charrel R.N., Gonzales J.P., Lukashevich I.S., Peters C.J., Rico-Hesse R., Romanowski V. Family Arenaviridae. Virus Taxonomy. Eighth Report of the International Committee on Taxonomy of Viruses, L.A. 2005, Academic Press. M.H.V. Van Regenmortel, C.M. Fauquet, M.A. Mayo, J. Maniloff, U. Desselberger, Ball (Eds.).
122. Salvato M.S., Shimomaye E.M. The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. Virology 1989, 173:1-10.
123. Schmaljohn C., Hjelle B. Hantaviruses: a global disease problem. Emerg. Infect. Dis. 1997, 3:95-104.
124. Sepúlveda C.S., Fascio M.L., Mazzucco M.B., Palacios M.L., Pellón R.F., García C.C., d'Accorso N.B., Damonte E.B. Synthesis and evaluation of N-substituted acridones as antiviral agents against haemorrhagic fever viruses. Antivir. Chem. Chemother. 2008, 19:41-47.
125. Severson W.E., Schmaljohn C.S., Javadian A., Jonsson C.B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 2003, 77:481-488.
126. Sewell D.L. Laboratory-associated infections and biosafety. Clin. Microbiol. Rev. 1995, 8:389-405.
127. Shaw M.W., Lamb R.A. A specific sub-set of host-cell mRNAs prime influenza virus mRNA synthesis. Virus Res. 1984, 1:455-467.
128. Singh M.K., Fuller-Pace F.V., Buchmeier M.J., Southern P.J. Analysis of the genomic L RNA segment from lymphocytic choriomeningitis virus. Virology 1987, 161:448-456.
129. Sohn Y.M., Rho H.O., Park M.S., Kim J.S., Summers P.L. Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea. Yonsei Med. J. 2001, 42(3):278-284.
130. Song J., Kang H.J., Song K.J., Truong T.T., Bennett S.N., Arai S., Truong N.U., Yanagihara R. Newfound hantavirus in Chinese mole shrew, Vietnam. Emerg. Infect. Dis. 2007, 13:1784-1787.
131. Song J.W., Gu S.H., Bennett S.N., Arai S., Puorger M., Hilbe M., Yanagihara R. Seewis virus, a genetically distinct hantavirus in the Eurasian common shrew (Sorex araneus). Virol. J. 2007, 4:114.
132. Song J.W., Kang H.J., Gu S.H., Moon S.S., Bennett S.N., Song K.J., Baek L.J., Kim H.C., O'Guinn M.L., Chong S.T., Klein T.A., Yanagihara R. Characterization of Imjin virus, a newly isolated hantavirus from the Ussuri white-toothed shrew (Crocidura lasiura). J. Virol. 2009, 83:6184-6191.
133. Southern P.J., Singh M.K., Riviere Y., Jacoby D.R., Buchmeier M.J., Oldstone M.B. Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology 1987, 157:145-155.
134. Spik K.W., Badger C., Mathiessen I., Tjelle T., Hooper J.W., Schmaljohn C. Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters. Vaccine 2008, 26(40):5177-5181.
135. Strecker T., Eichler R., ter Meulen J., Weissenhorn W., Klenk H.D., Garten W., Lenz O. Lassa virus Z protein is a matrix protein sufficient for the release of virus-like particles. J. Virol. 2003, 77:10700-10705.
136. Strecker T., Maisa A., Daffis S., Eichler R., Lenz O., Garten W. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol. J. 2006, 3:93.
137. Uckun F.M., Venkatachalam T.K., Erbeck D., Chen C.L., Petkevich A.S., Vassilev A. Zidampidine, an aryl phosphate derivative of AZT: in vivo pharmacokinetics, metabolism, toxicity, and anti-viral efficacy against haemorrhagic fever caused by Lassa virus. Bioorg. Med. Chem. 2005, 13:3279-3288.
138. Vieth S., Torda A.E., Asper M., Schmitz H., Günther S. Sequence analysis of L RNA of Lassa virus. Virology 2004, 318:153-168.
139. Vieth S., Drosten C., Lenz O., Vincent M., Omilabu S., Hass M., Becker-Ziaja B., ter Meulen J., Nichol S.T., Schmitz H., Günther S. RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:1253-1264.
140. York J., Dai D., Amberg S.M., Nunberg J.H. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J. Virol. 2008.
141. Wilda M., Lopez I., Casabona J.C., Franze-Fernandez M.T. Mapping of the Tacaribe arenavirus Z-protein binding sites on the L protein identified both amino acids within the putative polymerase domain and a region at the N terminus of L that are critically involved in binding. J. Virol. 2008, 82:11454-11460.
142. Woo G.J., Chun E.Y., Kim K.H., Kim W. Analysis of immune responses against nucleocapsid protein of the Hantaan virus elicited by virus infection or DNA vaccination. J. Microbiol. 2005, 43(6):537-545.